Teijin Pharma to Launch Ipsen’s Somatuline Subcutaneous Injection in Japan

Teijin Pharma and Ipsen announced the launch of Somatuline 60/90/120 mg for subcutaneous injection in Japan for the treatment of acromegaly and pituitary gigantism (when response to surgical therapies is not satisfactory or surgical therapies are difficult to perform).
BusinessWire